UBS AM
KYMR icon

UBS AM’s Kymera Therapeutics KYMR Stock Holding History

UBS AM’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.5M Sell
736,866
-139,006
-16% -$11.9M 0.02% 545
2026
Q1 		$73M Sell
875,872
-36,626
-4% -$2.9M 0.02% 560
2025
Q4 		$71M Buy
912,498
+48,736
+6% +$3.29M 0.02% 549
2025
Q3 		$48.9M Buy
863,762
+44,835
+5% +$2.02M 0.01% 604
2025
Q2 		$35.7M Sell
818,927
-77,477
-9% -$2.67M 0.01% 809
2025
Q1 		$24.5M Buy
896,404
+491,737
+122% +$17.9M 0.01% 879
2024
Q4 		$16.3M Sell
404,667
-23,862
-6% -$1.08M ﹤0.01% 1042
2024
Q3 		$20.3M Sell
428,529
-5,044
-1% -$223K 0.01% 945
2024
Q2 		$12.9M Buy
433,573
+253,635
+141% +$8.78M ﹤0.01% 1031
2024
Q1 		$7.23M Buy
179,938
+3,438
+2% +$123K ﹤0.01% 1116
2023
Q4 		$4.49M Sell
176,500
-13,233
-7% -$237K ﹤0.01% 1296
2023
Q3 		$2.64M Buy
189,733
+13,205
+7% +$265K ﹤0.01% 1485
2023
Q2 		$5.23M Hold
176,528
– – ﹤0.01% 1202
2023
Q1 		$5.23M Sell
176,528
-3,039
-2% -$98K ﹤0.01% 1202
2022
Q4 		$4.48M Buy
179,567
+12,022
+7% +$321K ﹤0.01% 1205
2022
Q3 		$3.65M Sell
167,545
-26,779
-14% -$706K ﹤0.01% 1316
2022
Q2 		$3.83M Sell
194,324
-235,919
-55% -$5.51M ﹤0.01% 1314
2022
Q1 		$18.2M Buy
430,243
+164,192
+62% +$6.93M 0.01% 867
2021
Q4 		$16.9M Sell
266,051
-238
-0.1% -$13.9K 0.01% 948
2021
Q3 		$15.6M Sell
266,289
-15,750
-6% -$913K 0.01% 936
2021
Q2 		$13.7M Buy
+282,039
New +$12.2M 0.01% 999

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS AM's KYMR Position: Q2 2026 in Review

UBS AM reduced its Kymera Therapeutics (KYMR) stake by 16% in Q2 2026, selling an estimated $11.9M and leaving 736,866 shares worth $84.5M. The position accounts for 0.02% of the portfolio, ranked #545.

UBS AM first reported a position in KYMR in Q2 2021 and has held it in 21 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • UBS AM held 736,866 shares of Kymera Therapeutics worth $84.5M as of Q2 2026.
  • UBS AM sold 139,006 Kymera Therapeutics shares in Q2 2026, an estimated $11.9M.
  • Kymera Therapeutics made up 0.02% of UBS AM's portfolio in Q2 2026, its #545 holding.
  • UBS AM first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.